The Pharma Letter M&A roundup - June 2022

1 July 2022

Rumors of a mega Merck & Co (NYSE: MRK) acquisition have been swirling round in recent weeks, and while the potential takeover of Seagen has not yet happened, a few noteworthy deals have been announced during June.

By far the biggest was Bristol Myers Squibb (NYSE: BMY) splashing out $4.1 billion on Turning Point Therapeutics to broaden an oncology franchise that is already one of the strongest in the industry.

The rest of the month's M&A activity included deals for privately-held German drugmaker Boehringer Ingelheim, mid-size French firm Ipsen (Euronext: IPN) and a couple for Belgian biotech company Galapagos (Euronext: GLPG).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK